Identification of RFC5 as a novel potential prognostic biomarker in lung cancer through bioinformatics analysis

Wang,Meng; Xie,Tian; Wu,Yingjie; Yin,Qian; Xie,Songping; Yao,Qingyu; Xiong,Jie; Zhang,Qiuping

doi:10.3892/ol.2018.9221

Identification of RFC5 as a novel potential prognostic biomarker in lung cancer through bioinformatics analysis

Authors:
- Meng Wang
- Tian Xie
- Yingjie Wu
- Qian Yin
- Songping Xie
- Qingyu Yao
- Jie Xiong
- Qiuping Zhang
View Affiliations

Affiliations: Department of Immunology, School of Basic Medical Science, Wuhan University, Wuhan, Hubei 430071, P.R. China, Department of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China, Department of Human Resource, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China
Published online on: July 26, 2018 https://doi.org/10.3892/ol.2018.9221
Pages: 4201-4210
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is the leading cause of mortalities among all types of cancer. Therefore, the screening of biomarkers that are related with the progression of lung cancer is crucial for early diagnosis and efficient therapy of lung cancer. In the present study, bioinformatic analysis identified replication factor C 5 (RFC5) as a potential novel oncogene in lung cancer. RFC5 functions as a clamp loader and is involved in DNA replication and repair. Analysis of public databases and reverse transcription‑quantitative polymerase chain reaction indicated that RFC5 was significantly increased in tumor tissues compared with adjacent normal tissues. A high RFC5 expression was observed to be associated with more aggressive malignant clinicopathological features, including higher T stage, more advanced regional lymph node metastasis and a higher probability of relapse. Notably, there were notable differences in overall survival (OS), first progression and post‑progression survival between the high RFC5 expression group and low RFC5 expression group. Univariate and multivariate Cox regression analyses indicated that RFC5 was an independent risk factor that was associated with poorer OS and disease‑free survival. According to GSEA, several gene sets that are associated with cell cycle and DNA damage were enriched in the RFC5 overexpression group, which indicated that RFC5 might promote the proliferation of lung cancer cells. Our finding indicated that RFC5 might be a novel prognostic biomarker of lung cancer, and it might be serve as a potential diagnosis and therapy target for lung cancer in the future.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer Statistics, 2017. CA A Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar
2	Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 66:271–289. 2016. View Article : Google Scholar : PubMed/NCBI
3	Torre LA, Siegel RL and Jemal A: Lung Cancer Statistics. Adv Exp Med Biol. 893:1–19. 2016. View Article : Google Scholar : PubMed/NCBI
4	Sung WJ, Kim H and Park KK: The biological role of epithelial-mesenchymal transition in lung cancer (Review). Oncol Rep. 36:1199–1206. 2016. View Article : Google Scholar : PubMed/NCBI
5	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
6	Kato T, Yoshioka H, Okamoto I, Yokoyama A, Hida T, Seto T, Kiura K, Massey D, Seki Y and Yamamoto N: Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3. Cancer Sci. 106:1202–1211. 2015. View Article : Google Scholar : PubMed/NCBI
7	Hoshi H, Hiyama G, Ishikawa K, Inageda K, Fujimoto J, Wakamatsu A, Togashi T, Kawamura Y, Takahashi N, Higa A, et al: Construction of a novel cell-based assay for the evaluation of anti-EGFR drug efficacy against EGFR mutation. Oncol Rep. 37:66–76. 2017. View Article : Google Scholar : PubMed/NCBI
8	Li K, Yang M, Liang N and Li S: Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution (Review). Oncol Rep. 37:1347–1358. 2017. View Article : Google Scholar : PubMed/NCBI
9	Juan O and Popat S: Crizotinib for ROS1 patients: One small step in biomarker testing, one giant leap for advanced NSCLC patients. Lung Cancer. 104:131–133. 2017. View Article : Google Scholar : PubMed/NCBI
10	Chen M, Pan ZQ and Hurwitz J: Studies of the cloned 37-kDa subunit of activator 1 (replication factor C) of HeLa cells. Proc Natl Acad Sci USA. 89:5211–5215. 1992. View Article : Google Scholar : PubMed/NCBI
11	Virshup DM and Kelly TJ: Purification of replication protein C, a cellular protein involved in the initial stages of simian virus 40 DNA replication in vitro. Proc Natl Acad Sci USA. 86:3584–3588. 1989. View Article : Google Scholar : PubMed/NCBI
12	Uhlmann F, Cai J, Flores-Rozas H, Dean FB, Finkelstein J, O'Donnell M and Hurwitz J: In vitro reconstitution of human replication factor C from its five subunits. Proc Natl Acad Sci USA. 93:6521–6526. 1996. View Article : Google Scholar : PubMed/NCBI
13	Cullmann G, Fien K, Kobayashi R and Stillman B: Characterization of the five replication factor C genes of Saccharomyces cerevisiae. Mol Cell Biol. 15:4661–4671. 1995. View Article : Google Scholar : PubMed/NCBI
14	Majka J and Burgers PM: The PCNA-RFC families of DNA clamps and clamp loaders. Prog Nucleic Acid Res Mol Biol. 78:227–260. 2004. View Article : Google Scholar : PubMed/NCBI
15	Zhang G, Gibbs E, Kelman Z, O'Donnell M and Hurwitz J: Studies on the interactions between human replication factor C and human proliferating cell nuclear antigen. Proc Natl Acad Sci USA. 96:1869–1874. 1999. View Article : Google Scholar : PubMed/NCBI
16	Niu G, Wang D, Pei Y and Sun L: Systematic identification of key genes and pathways in the development of invasive cervical cancer. Gene. 618:28–41. 2017. View Article : Google Scholar : PubMed/NCBI
17	Chae HD, Mitton B, Lacayo NJ and Sakamoto KM: Replication factor C3 is a CREB target gene that regulates cell cycle progression through the modulation of chromatin loading of PCNA. Leukemia. 29:1379–1389. 2015. View Article : Google Scholar : PubMed/NCBI
18	Xiang J, Fang L, Luo Y, Yang Z, Liao Y, Cui J, Huang M, Yang Z, Huang Y, Fan X, et al: Levels of human replication factor C4, a clamp loader, correlate with tumor progression and predict the prognosis for colorectal cancer. J Transl Med. 12:3202014. View Article : Google Scholar : PubMed/NCBI
19	Lockwood WW, Thu KL, Lin L, Pikor LA, Chari R, Lam WL and Beer DG: Integrative genomics identified RFC3 as an amplified candidate oncogene in esophageal adenocarcinoma. Clin Cancer Res. 18:1936–1946. 2012. View Article : Google Scholar : PubMed/NCBI
20	Arai M, Kondoh N, Imazeki N, Hada A, Hatsuse K, Matsubara O and Yamamoto M: The knockdown of endogenous replication factor C4 decreases the growth and enhances the chemosensitivity of hepatocellular carcinoma cells. Liver Int. 29:55–62. 2009. View Article : Google Scholar : PubMed/NCBI
21	Murakami T, Takano R, Takeo S, Taniguchi R, Ogawa K, Ohashi E and Tsurimoto T: Stable interaction between the human proliferating cell nuclear antigen loader complex Ctf18-replication factor C (RFC) and DNA polymerase {epsilon} is mediated by the cohesion-specific subunits, Ctf18, Dcc1 and Ctf8. J Biol Chem. 285:34608–34615. 2010. View Article : Google Scholar : PubMed/NCBI
22	Maradeo ME, Garg A and Skibbens RV: Rfc5p regulates alternate RFC complex functions in sister chromatid pairing reactions in budding yeast. Cell Cycle. 9:4370–4378. 2010. View Article : Google Scholar : PubMed/NCBI
23	Peng WX, Han X, Zhang CL, Ge L, Du FY, Jin J and Gong AH: FoxM1-mediated RFC5 expression promotes temozolomide resistance. Cell Biol Toxicol. 33:527–537. 2017. View Article : Google Scholar : PubMed/NCBI
24	Liu SM, Chen W and Wang J: Distinguishing between cancer cell differentiation and resistance induced by all-trans retinoic acid using transcriptional profiles and functional pathway analysis. Sci Rep. 4:55772014. View Article : Google Scholar : PubMed/NCBI
25	Klein D: Quantification using real-time PCR technology: Applications and limitations. Trends Mol Med. 8:257–260. 2002. View Article : Google Scholar : PubMed/NCBI
26	Gyorffy B, Surowiak P, Budczies J and Lanczky A: Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One. 8:e822412013. View Article : Google Scholar : PubMed/NCBI
27	Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q and Szallasi Z: An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 123:725–731. 2010. View Article : Google Scholar : PubMed/NCBI
28	Gyorffy B, Lanczky A and Szallasi Z: Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer. 19:197–208. 2012. View Article : Google Scholar : PubMed/NCBI
29	Szasz AM, Lanczky A, Nagy A, Förster S, Hark K, Green JE, Boussioutas A, Busuttil R, Szabó A and Győrffy B: Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients. Oncotarget. 7:49322–49333. 2016. View Article : Google Scholar : PubMed/NCBI
30	Gorbea CM, Marchand P, Jiang W, Copeland NG, Gilbert DJ, Jenkins NA and Bond JS: Cloning, expression and chromosomal localization of the mouse meprin beta subunit. J Biol Chem. 268:21035–21043. 1993.PubMed/NCBI
31	Shimada M, Okuzaki D, Tanaka S, Tougan T, Tamai KK, Shimoda C and Nojima H: Replication factor C3 of Schizosaccharomyces pombe, a small subunit of replication factor C complex, plays a role in both replication and damage checkpoints. Mol Bio Cell. 10:3991–4003. 1999. View Article : Google Scholar
32	Naiki T, Shimomura T, Kondo T, Matsumoto K and Sugimoto K: Rfc5, in cooperation with rad24, controls DNA damage checkpoints throughout the cell cycle in Saccharomyces cerevisiae. Mol Cell Biol. 20:5888–5896. 2000. View Article : Google Scholar : PubMed/NCBI
33	Kim HS and Brill SJ: Rfc4 interacts with Rpa1 and is required for both DNA replication and DNA damage checkpoints in Saccharomyces cerevisiae. Mol Cell Biol. 21:3725–3737. 2001. View Article : Google Scholar : PubMed/NCBI
34	Tomida J, Masuda Y, Hiroaki H, Ishikawa T, Song I, Tsurimoto T, Tateishi S, Shiomi T, Kamei Y, Kim J, et al: DNA damage-induced ubiquitylation of RFC2 subunit of replication factor C complex. J Biol Chem. 283:9071–9079. 2008. View Article : Google Scholar : PubMed/NCBI
35	Shiomi Y, Usukura J, Masamura Y, Takeyasu K, Nakayama Y, Obuse C, Yoshikawa H and Tsurimoto T: ATP-dependent structural change of the eukaryotic clamp-loader protein, replication factor C. Proc Natl Acad Sci USA. 97:14127–14132. 2000. View Article : Google Scholar : PubMed/NCBI
36	Munshi A, Cannella D, Brickner H, Salles-Passador I, Podust V, Fotedar R and Fotedar A: Cell cycle-dependent phosphorylation of the large subunit of replication factor C (RF-C) leads to its dissociation from the RF-C complex. J Biol Chem. 278:48467–48473. 2003. View Article : Google Scholar : PubMed/NCBI
37	Qi S, Wang CH, Li CL, Wang P and Liu MH: Candidate genes investigation for severe nonalcoholic fatty liver disease based on bioinformatics analysis. Medicine (Baltimore). 96:e77432017. View Article : Google Scholar : PubMed/NCBI
38	Arnold BN, Thomas DC, Rosen JE, Salazar MC, Detterbeck FC, Blasberg JD, Boffa DJ and Kim AW: Effectiveness of local therapy for stage I non-small-cell lung cancer in nonagenarians. Surgery. 162:640–651. 2017. View Article : Google Scholar : PubMed/NCBI
39	Koch HB, Zhang R, Verdoodt B, Bailey A, Zhang CD, Yates JR III, Menssen A and Hermeking H: Large-scale identification of c-MYC-associated proteins using a combined TAP/MudPIT approach. Cell cycle. 6:205–217. 2007. View Article : Google Scholar : PubMed/NCBI
40	Erdogan E, Klee EW, Thompson EA and Fields AP: Meta-analysis of oncogenic protein kinase Ciota signaling in lung adenocarcinoma. Clin Cancer Res. 15:1527–1533. 2009. View Article : Google Scholar : PubMed/NCBI
41	Kang BY, You H, Bandyopadhyay S, Agrawal N, Melchert RB, Basnakian AG, Liu Y and Hermonat PL: Cervical cancer isolate PT3, super-permissive for adeno-associated virus replication, over-expresses DNA polymerase delta, PCNA, RFC and RPA. BMC Microbiol. 9:792009. View Article : Google Scholar : PubMed/NCBI
42	Narayan G, Bourdon V, Chaganti S, Arias-Pulido H, Nandula SV, Rao PH, Gissmann L, Dürst M, Schneider A, Pothuri B, et al: Gene dosage alterations revealed by cDNA microarray analysis in cervical cancer: Identification of candidate amplified and overexpressed genes. Genes chromosomes cancer. 46:373–384. 2007. View Article : Google Scholar : PubMed/NCBI
43	Slebos RJ, Yi Y, Ely K, Carter J, Evjen A, Zhang X, Shyr Y, Murphy BM, Cmelak AJ and Burkey BB: Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research. 12:701–709. 2006. View Article : Google Scholar : PubMed/NCBI